166 related articles for article (PubMed ID: 38498998)
21. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
22. A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment.
Bellat V; Alcaina Y; Tung CH; Ting R; Michel AO; Souweidane M; Law B
Neuro Oncol; 2020 Oct; 22(10):1495-1504. PubMed ID: 32301996
[TBL] [Abstract][Full Text] [Related]
23. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
[TBL] [Abstract][Full Text] [Related]
24. P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.
Duan JJ; Chen L; Xue CB; Wasserman ZR; Hardman KD; Covington MB; Copeland RR; Arner EC; Decicco CP
Bioorg Med Chem Lett; 1999 May; 9(10):1453-8. PubMed ID: 10360755
[TBL] [Abstract][Full Text] [Related]
25. PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38319732
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
[TBL] [Abstract][Full Text] [Related]
27. Preclinical and clinical investigation of intratumoral chemotherapy pharmacokinetics in DIPG using gemcitabine.
Green AL; Flannery P; Hankinson TC; O'Neill B; Amani V; DeSisto J; Knox A; Chatwin H; Lemma R; Hoffman LM; Mulcahy Levy J; Raybin J; Hemenway M; Gilani A; Koschmann C; Dahl N; Handler M; Pierce A; Venkataraman S; Foreman N; Vibhakar R; Wempe MF; Dorris K
Neurooncol Adv; 2020; 2(1):vdaa021. PubMed ID: 32642682
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist.
Yang Z; Fang Y; Park H
Bioorg Med Chem Lett; 2017 Jun; 27(11):2515-2519. PubMed ID: 28408218
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
[TBL] [Abstract][Full Text] [Related]
30. Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy.
Shan S; Chen J; Sun Y; Wang Y; Xia B; Tan H; Pan C; Gu G; Zhong J; Qing G; Zhang Y; Wang J; Wang Y; Wang Y; Zuo P; Xu C; Li F; Guo W; Xu L; Chen M; Fan Y; Zhang L; Liang XJ
Adv Sci (Weinh); 2022 Jul; 9(21):e2200353. PubMed ID: 35585670
[TBL] [Abstract][Full Text] [Related]
31. Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue.
Heravi Shargh V; Luckett J; Bouzinab K; Paisey S; Turyanska L; Singleton WGB; Lowis S; Gershkovich P; Bradshaw TD; Stevens MFG; Bienemann A; Coyle B
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35266-35280. PubMed ID: 34310112
[TBL] [Abstract][Full Text] [Related]
32. Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma.
Misuraca KL; Cordero FJ; Becher OJ
Front Oncol; 2015; 5():172. PubMed ID: 26258075
[TBL] [Abstract][Full Text] [Related]
33. Clinical trials for diffuse intrinsic pontine glioma: the current state of affairs.
Rechberger JS; Lu VM; Zhang L; Power EA; Daniels DJ
Childs Nerv Syst; 2020 Jan; 36(1):39-46. PubMed ID: 31489454
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
[TBL] [Abstract][Full Text] [Related]
35. TSPO PET Imaging as a Potent Non-Invasive Biomarker for Diffuse Intrinsic Pontine Glioma in a Patient-Derived Orthotopic Rat Model.
Chevaleyre C; Kereselidze D; Caillé F; Tournier N; Olaciregui NG; Winkeler A; Declèves X; Jego B; Cisternino S; Auvity S; Truillet C
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293329
[TBL] [Abstract][Full Text] [Related]
36. Diffuse intrinsic pontine glioma: current insights and future directions.
Srikanthan D; Taccone MS; Van Ommeren R; Ishida J; Krumholtz SL; Rutka JT
Chin Neurosurg J; 2021 Jan; 7(1):6. PubMed ID: 33423692
[TBL] [Abstract][Full Text] [Related]
37. Repurposing Vandetanib plus Everolimus for the Treatment of
Carvalho DM; Richardson PJ; Olaciregui N; Stankunaite R; Lavarino C; Molinari V; Corley EA; Smith DP; Ruddle R; Donovan A; Pal A; Raynaud FI; Temelso S; Mackay A; Overington JP; Phelan A; Sheppard D; Mackinnon A; Zebian B; Al-Sarraj S; Merve A; Pryce J; Grill J; Hubank M; Cruz O; Morales La Madrid A; Mueller S; Carcaboso AM; Carceller F; Jones C
Cancer Discov; 2022 Feb; 12(2):416-431. PubMed ID: 34551970
[TBL] [Abstract][Full Text] [Related]
38. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).
Gwak HS; Park HJ
Crit Rev Oncol Hematol; 2017 Dec; 120():111-119. PubMed ID: 29198324
[TBL] [Abstract][Full Text] [Related]
39. MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma.
Ishida J; Alli S; Bondoc A; Golbourn B; Sabha N; Mikloska K; Krumholtz S; Srikanthan D; Fujita N; Luck A; Maslink C; Smith C; Hynynen K; Rutka J
J Control Release; 2021 Feb; 330():1034-1045. PubMed ID: 33188825
[TBL] [Abstract][Full Text] [Related]
40. Pediatric diffuse intrinsic pontine glioma: where do we stand?
Rashed WM; Maher E; Adel M; Saber O; Zaghloul MS
Cancer Metastasis Rev; 2019 Dec; 38(4):759-770. PubMed ID: 31802357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
